Medicus Pharma initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $9 price target The firm projects growing revenue from the company’s doxorubicin- microneedle array in basal cell carcinoma, BCC, with projected cash of $15.6M to fund operations into Q3 of this year, the analyst tells investors in a research note. Near-term catalysts for Medicus include the presentation of Phase 1 results in healthy premenopausal women evaluating single-dose subcutaneous administration of Teverelix, detailed D-MNA Phase 2 results, and the start of enrollment for its Phase 2b Teverelix trial in high cardiovascular risk APC, all 3 of which will occur later this quarter, followed by an anticipated end-of-Phase 2 meeting in Q3, and the start of enrollment into its Phase 2 Teverelix trial for AURr by 2026-end, Roth added.